Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

However, as this did not reach statistical significance, only nominal p values were generated for lower-ranking end points in the hierarchical testing.

also in 111,027 other papers

There was a nominally significant improvement with abatacept versus placebo in adjusted mean change from baseline to week 24 in DAPSA score (–18.75 vs –13.00; adjusted difference –5.75; 95% CI –10.01 to –1.49; nominal p=0.008).

also in 7,732 other papers